These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8819514)

  • 21. Rapid tolerance to Delta(9)-tetrahydrocannabinol and cross-tolerance between ethanol and Delta(9)-tetrahydrocannabinol in mice.
    da Silva GE; Morato GS; Takahashi RN
    Eur J Pharmacol; 2001 Nov; 431(2):201-7. PubMed ID: 11728426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.
    Trexler KR; Nass SR; Crowe MS; Gross JD; Jones MS; McKitrick AW; Siderovski DP; Kinsey SG
    Drug Alcohol Depend; 2018 Oct; 191():14-24. PubMed ID: 30071445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice.
    Valverde O; Maldonado R; Valjent E; Zimmer AM; Zimmer A
    J Neurosci; 2000 Dec; 20(24):9284-9. PubMed ID: 11125007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum.
    Tzavara ET; Valjent E; Firmo C; Mas M; Beslot F; Defer N; Roques BP; Hanoune J; Maldonado R
    Eur J Neurosci; 2000 Mar; 12(3):1038-46. PubMed ID: 10762335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.
    Compton DR; Aceto MD; Lowe J; Martin BR
    J Pharmacol Exp Ther; 1996 May; 277(2):586-94. PubMed ID: 8627535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of gonadal hormones on cannabinoid dependence.
    Marusich JA; Craft RM; Lefever TW; Wiley JL
    Exp Clin Psychopharmacol; 2015 Aug; 23(4):206-16. PubMed ID: 26237318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of sex differences in cannabinoid dependence.
    Marusich JA; Lefever TW; Antonazzo KR; Craft RM; Wiley JL
    Drug Alcohol Depend; 2014 Apr; 137():20-8. PubMed ID: 24582909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesolimbic dopaminergic decline after cannabinoid withdrawal.
    Diana M; Melis M; Muntoni AL; Gessa GL
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10269-73. PubMed ID: 9707636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
    Adams IB; Compton DR; Martin BR
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attenuation of delta 9-tetrahydrocannabinol-induced withdrawal-like behaviour by delta 9-tetrahydrocannabinol.
    Verberne AJ; Taylor DA; Fennessy MR
    Psychopharmacology (Berl); 1981; 73(1):97-8. PubMed ID: 6262850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Marijuana withdrawal syndrome in the animal model.
    Lichtman AH; Martin BR
    J Clin Pharmacol; 2002 Nov; 42(S1):20S-27S. PubMed ID: 12412832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methysergide-induced precipitated withdrawal syndrome in phencyclidine-dependent rats.
    Nabeshima T; Ishikawa K; Yamaguchi K; Furukawa H; Kameyama T
    Neurosci Lett; 1986 Sep; 69(3):275-8. PubMed ID: 3763058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Antagonist"-precipitated withdrawal in the rat after chronic delta9-tetrahydrocannabinol treatment.
    Taylor DA; Fennessy MR
    J Pharm Pharmacol; 1978 Oct; 30(10):654-6. PubMed ID: 30825
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of delta-9-tetrahydrocannabinol on barbiturate withdrawal convulsions in the rat.
    Gildea ML; Bourn WM
    Life Sci; 1977 Sep; 21(6):829-32. PubMed ID: 562463
    [No Abstract]   [Full Text] [Related]  

  • 35. Nicotine and Delta(9)-tetrahydrocannabinol withdrawal induce Narp in the central nucleus of the amygdala.
    Reti IM; Han S; Miskimon M; Rosen JB; Baraban JM
    Synapse; 2009 Mar; 63(3):252-5. PubMed ID: 19084905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative allosteric modulation of CB
    Iyer V; Saberi SA; Pacheco R; Sizemore EF; Stockman S; Kulkarni A; Cantwell L; Thakur GA; Hohmann AG
    Neuropharmacology; 2024 Oct; 257():110052. PubMed ID: 38936657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Δ
    Marusich JA; Wiley JL
    Drug Alcohol Depend Rep; 2023 Dec; 9():100205. PubMed ID: 38045495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Potential of Cannabis: A Comprehensive Review of Current and Future Applications.
    Leinen ZJ; Mohan R; Premadasa LS; Acharya A; Mohan M; Byrareddy SN
    Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37893004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Δ
    Laudermilk LT; Marusich JA; Wiley JL
    Cardiovasc Toxicol; 2023 Dec; 23(11-12):349-363. PubMed ID: 37728714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of dependence potential and abuse liability of Δ
    Vanegas SO; Reck AM; Rodriguez CE; Marusich JA; Yassin O; Sotzing G; Wiley JL; Kinsey SG
    Drug Alcohol Depend; 2022 Nov; 240():109640. PubMed ID: 36179506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.